DDInter817 DDInter1016
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deutetrabenazine
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Dronedarone
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Gilteritinib may lead to a major life threatening interaction when taken with Dronedarone
Gilteritinib may lead to a major life threatening interaction when taken with Troleandomycin